Short communication · 24 Nov 2021
Conference abstractPublished 20 Nov 2013
CPE-deltaN: A powerful diagnostic and predictive biomarker for metastasis in different types of human cancers
Section on Cellular Neurobiology, Program on Developmental Neuroscience, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, USA Department of Surgery, University of Hong Kon, China Departm
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Metastasis is a major cause of mortality in cancer patients. Currently, few accurate biomarkers exist for predicting future metastasis to guide therapy. Here we report that CPE-deltaN, a splice isoform of the carboxypeptidase E gene is a prognostic biomarker. CPE-deltaN drives metastasis by interacting with histone deacetylase 1/2 to up-regulate expression of metastatic gene Nedd9. CPE-deltaN mRNA is elevated in human metastatic colon, breast, prostate, head and neck, glioblastoma and HCC cell lines. In clinical studies on 99 patients with hepatocellular carcinoma (HCC), a common cancer worldwide, CPEdeltaN mRNA quantification in the resected primary tumor (T) and normal surrounding tissue (N) established a T/N cut off value which predicted future intra-hepatic metastasis at 2 years with high sensitivity (92%) and specificity (76%), independent of cancer stage (J. Clin. Invest. 121:880-892, 2011). Additionally, a study on 68 patients with colorectal cancer showed that T/N of CPE-Ã?Â?N mRNA above the cutoff accurately diagnosed metastatic tumors. In another study, resected PHEO/PGLs having very high CPE-deltaN mRNA copy numbers accurately predicted future metastasis or recurrence in patients diagnosed with benign tumors at time of surgery, versus low copy numbers in post surgery, disease-free patients, with sensitivity and specificity values of 100%. Thus CPE-deltaN is a powerful biomarker for diagnosing and predicting future metastasis and recurrence in HCC, PHEO/ PGL and colorectal carcinoma patients, superior to the histopathological diagnosis currently available. On-going clinical studies suggest that CPE-deltaN is a prognostic biomarker for other types of cancers as well which will be discussed.
Subjects
BiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 17 Aug 2015
Proteome-based development of biomarkers predicting risk of cancer metastasis
Conference abstract · 20 Jun 2013
Recent advances in biomarkers for predicting cancer metastasis
Research article · 19 Sep 2017
Diagnostic values of serum TRACP5b, CEA and CA-153 in predicting bone metastasis in lymph node-negative breast cancer patients
Conference abstract · 2022
Expression of biomarkers vimentin and metastasis associated 1(MTA1) protein in different stages of laryngeal cancer and their impacs on survival
More from this journal
The newest in Journal of Cell Science & Therapy.
Perspective · 2 Feb 2026
Exploring Senescence and Its Influence on Tissue Function and Therapeutic Research
Commentary · 2 Feb 2026
Metabolism Regulation and Its Influence on Therapeutic Development in Human Disease
Commentary · 2 Dec 2025
Cellular Membranes and Transport Proteins as Regulators of Homeostasis and Metabolic Coordination
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Cell Science & Therapy
- SubjectBiology
- BylineArticles whose byline prints “Y. Peng Loh”
- BylineArticles whose byline prints “Saravana RK. Murthy”
- BylineArticles whose byline prints “Terence Lee”
- BylineArticles whose byline prints “Ronnie T. Poon”
- BylineArticles whose byline prints “Karel Pacak”

